The company's strategy is synthesis of compounds, preliminary pharmacology, and biological screening against bacteria and parasites. Candidate drugs against malaria and leishmaniasis have been seleceted for further development. Antibacterial compounds with in vitro efficacy against resistant bacteria such as MRSAs, VREs, and penicillin-resistant sterptococci have been identified.